Zentralnervöse Vaskulitiden bei rheumatischen Erkrankungen

Zusammenfassung

Die Beteiligung des zentralen Nervensystems (ZNS) im Rahmen von Erkrankungen aus dem rheumatischen Formenkreis stellt eine ernsthafte Bedrohung für den Patienten dar. Sie rechtfertigt in der Regel eine aggressive immunsuppressive Therapie. Die klinische Manifestation hängt von der Größe und Lokalisation der betroffenen Arterien ab. Im Falle einer Vaskulitis großer und mittelgroßer Arterien dominieren neurologische Herdsymptome, die apoplektiform auftreten und zumeist auf ischämische Hirninfarkte (Territorialinfarkte) zurückzuführen sind. Häufiger handelt es sich aber um eine Vaskulitis der kleinen Arterien und die klinische Symptomatik ist eher diffus. Kopfschmerzen und ein hirnorganisches Psychosyndrom sind dann die Leitsymptome. Die paraklinischen Befunde (Liquor, MRT) sind unspezifisch, erlauben aber nicht selten den Beweis eines entzündlichen ZNS-Prozesses. Bildgebende Verfahren können hilfreich sein, andere zentralnervöse Manifestationen wie granulomatöse Enzephalitiden oder Meningitiden von rein vaskulären Syndromen abzugrenzen. Die Prognose der Grunderkrankung verschlechtert sich im Allgemeinen durch das Auftreten einer ZNS-Beteiligung.

Cerebral Vasculitis in Rheumatic Disorders

Involvement of the central nervous systems in rheumatic disorders is a serious threat to patients. Normally it justifies a reinforcement of immunosuppressive treatment. Clinical manifestations depend on the size and localisation of involved vessels. In case of vasculitis of large arteries, focal neurological signs and symptoms like hemiparesis determine the clinical picture. These symptoms appear suddenly and are a consequence of local ischaemic brain infarctions. More often small vessels are involved, which leads to diffuse neurological symptoms such as headache and organic brain syndrome with e. g. disturbed memory or personality changes. Diagnostic procedures include analysis of the cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI). Both may allow the proof of inflammatory CNS disease, but are not specific for vasculitis. MRI may be helpful to distinguish granulomatous encephalitis and meningitis from vasculitis. In general, CNS involvement in systemic rheumatic diseases worsens the prognosis and should therefore be taken seriously.

Literatur

• 1 Allen N B. Miscellaneous vasculitic syndromes including Behçet’s disease and central nervous system vasculitis.  Curr Opin Rheumatol. 1993;  5 51-56
• 2 Alrawi A, Trobe J D, Blaivas M, Musch D C. Brain biopsy in primary angiitis of the central nervous system.  Neurology. 1999;  53 858-860
• 3 Ando Y, Kai S, Uyama E, Iyonaga K, Hashimoto Y, Uchino M, Ando M. Involvement of the central nervous system in rheumatoid arthritis: its clinical manifestations and analysis by magnetic resonance imaging.  Intern Med. 1995;  34 188-191
• 4 Berlit T. Vaskulitis.  Ther Umsch. 1996;  53 559-567
• 5 Brooks W M, Sabet A, Sibbitt W L Jr, Barker P B, van Zijl P C, Duyn J H, Moonen C T. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus.  J Rheumatol. 1997;  24 2323-2329
• 6 Calabrese L H. Vasculitis of the central nervous system.  Rheum Dis Clin North Am. 1995;  21 1059-1076
• 7 Calabrese L H, Duna G F. Evaluation and treatment of central nervous system vasculitis.  Curr Opin Rheumatol. 1995;  7 37-44
• 8 Calabrese L H, Duna G F, Lie J T. Vasculitis in the central nervous system.  Arthritis Rheum. 1997;  40 1189-1201
• 9 Chen C L, Chiou Y H, Wu C Y, Lai P H, Chung H M. Cerebral vasculitis in Henoch-Schönlein purpura: a case report with sequential magnetic resonance imaging changes and treated with plasmapheresis alone.  Pediatr Nephrol. 2000;  15 276-278
• 10 Dahlberg P J, Lockhart J M, Overholt E L. Diagnostic studies for systemic necrotizing vasculitis. Sensitivity, specificity, and predictive value in patients with multisystem disease.  Arch Intern Med. 1989;  149 161-165
• 11 Felgenhauer K, Beuche W. Labordiagnostik neurologischer Erkrankungen. Stuttgart; Thieme 1999
• 12 Felgenhauer K, Reiber H. The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system.  Clin Investig. 1992;  70 28-37
• 13 Golombek S J, Graus F, Elkon K B. Autoantibodies in the cerebrospinal fluid of patients with systemic lupus erythematosus.  Arthritis Rheum. 1986;  29 1090-1097
• 14 Gonzalez-Crespo M R, Blanco F J, Ramos A, Ciruelo E, Mateo I, Lopez Pino M A, Gomez-Reino J J. Magnetic resonance imaging of the brain in systemic lupus erythematosus.  Br J Rheumatol. 1995;  34 1055-1060
• 15 Hara M, Goodman P C, Leder R A. FDG-PET finding in early-phase Takayasu arteritis.  J Comput Assist Tomogr. 1999;  23 16-18
• 16 Higashi Y, Kanekura T, Fukumaru K, Kanzaki T. Scleroderma on coup de sabre with central nervous system involvement.  J Dermatol. 2000;  27 486-488
• 17 Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C, Maestre J, Fabien N, Vighetto A, Casamitjana R, Thivolet C, Tavolato B, Antoine J, Trouillas P, Graus F. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients.  Arch Neurol. 2001;  58 225-230
• 18 Kao C H, Lan J L, ChangLai S P, Liao K K, Yen R F, Chieng P U. The role of FDG-PET, HMPAO-SPET and MRI in the detection of brain involvement in patients with systemic lupus erythematosus.  Eur J Nucl Med. 1999;  26 129-134
• 19 Kozora E, West S G, Kotzin B L, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease.  Arthritis Rheum. 1998;  41 41-47
• 20 McLean B N, Miller D, Thompson E J. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet’s disease involving the nervous system.  J Neurol Neurosurg Psychiatry. 1995;  58 548-554
• 21 Merkel P A, Koroshetz W J, Irizarry M C, Cudkowicz M E. Cocaine-associated cerebral vasculitis.  Semin Arthritis Rheum. 1995;  25 172-183
• 22 Mesec A, Rot U, Perkovic T, Lunder T, Sibane B. Carbamazepine hypersensitivity syndrome presenting as vasculitis of the CNS.  J Neurol Neurosurg Psychiatry. 1999;  66 249-250
• 23 Miguel E C, Pereira R M, Pereira C A, Baer L, Gomes R E, de Sa L C, Hirsch R, de Barros N G, de Navarro J M, Gentil V. Psychiatric manifestations of systemic lupus erythematosus: clinical features, symptoms, and signs of central nervous system activity in 43 patients.  Medicine (Baltimore). 1994;  73 224-232
• 24 Mitchell I, Hughes R AC, Maisey M, Cameron S. Cerebral lupus.  Lancet. 1994;  343 579-582
• 25 Moore P M. Neurological manifestation of vasculitis: update on immunopathogenic mechanisms and clinical features.  Ann Neurol. 1995;  37 131-141
• 26 Neumann-Andersen G, Lindgren S. Involvement of the entire spinal cord and medulla oblongata in acute catastrophic-onset transverse myelitis in SLE.  Clin Rheumatol. 2000;  19 156-160
• 27 Nishino H, Rubino F A, DeRemee R A, Swanson J W, Parisi J E. Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic.  Ann Neurol. 1993;  33 4-9
• 28 Nishino H, Rubino F A, Parisi J E. The spectrum of neurologic involvement in Wegener’s granulomatosis.  Neurology. 1993;  43 1334-1337
• 29 Rehman H U. Primary angiitis of the central nervous system.  J R Soc Med. 2000;  93 586-588
• 30 Scolding N J, Jayne D R, Zajicek J P, Meyer P A, Wraight E P, Lockwood C M. Cerebral vasculitis-recognition, diagnosis and management.  QJM. 1997;  90 61-73
• 31 Somer T, Finegold S M. Vasculitides associated with infections, immunization, and antimicrobial drugs.  Clin Infect Dis. 1995;  20 1010-1036
• 32 Spranger M, Schwab S, Meinck H M, Tischendorf M, Sis J, Breitbart A, Andrassy K. Meningeal involvement in Wegener’s granulomatosis confirmed and monitored by positive circulating antineutrophil cytoplasm in cerebrospinal fluid.  Neurology. 1997;  48 263-265
• 33 Tishler M, Alosachie I, Chapman Y, Korcyn A, Lorber M, Mevorach D, Tane D, Barka N, Lin H C, Alarcon-Segovia D et al. Anti-neuronal antibodies in antiphospholipid syndrome with central nervous system involvement: the difference from systemic lupus erythematosus.  Lupus. 1995;  4 145-147
• 34 Toubi E, Khamashta M A, Panarra A, Hughes G R. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus.  Am J Med. 1995;  99 397-401
• 35 Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, Batteux F, Stievenart J L, Weill B, Lubetzki C, Lyon-Caen O. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study.  Arch Neurol. 1998;  55 517-521
• 36 Trapp B D, Peterson J, Ransohoff R M, Rudick R, Mork S, Bö L. Axonal transection in the lesions of multiple sclerosis.  N Engl J Med. 1998;  338 278-285
• 37 Tribe C R, Scott D G, Bacon P A. Rectal biopsy in the diagnosis of systemic vasculitis.  J Clin Pathol. 1981;  34 843-850
• 38 Valesini G, Priori R, Francia A, Balestrieri G, Tincani A, Airo P, Cattaneo R, Zambruni A, Troianello B, Chofflon M et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate.  Springer Semin Immunopathol. 1994;  16 313-321
• 39 West L G. Lupus and the central nervous system.  Curr Opin Rheumatol. 1996;  8 408-414